Form 4: XBiotech Director Granted Stock Options

XBiotech Inc. Director Craig Rademaker received 92,104 stock options at an exercise price of $2.64, vesting over ten months.

Summary

• Craig Evan Rademaker, a Director of XBiotech Inc. (XBIT), was granted nonstatutory stock options.
• The grant, made on October 1, 2025, is for 92,104 shares of the Company's Common Stock.
• The exercise price for these options is $2.64 per share, which was the closing sales price on the grant date.
• The options were granted under the Company's 2025 Equity Incentive Plan.
• Vesting occurs in two equal portions: the first at four months (February 1, 2026) and the second at ten months (August 1, 2026) from the grant date.
• The options have an expiration date of October 1, 2035, ten years from the grant date.

Sentiment

Score: 6

Explanation: Slightly positive, as it aligns director incentives with shareholder interests, but it is a routine compensation event and not indicative of significant operational news.

Positives

• The grant of stock options aligns the director's financial interests with those of the shareholders, incentivizing long-term company performance.
• The options were issued under an established equity incentive plan (2025 Equity Incentive Plan), indicating a structured approach to executive compensation.

Future Outlook

The grant of stock options provides a future incentive for the director, with vesting scheduled over the next ten months and an expiration date ten years out, linking compensation to the company's long-term stock performance.

Management Comments

• On October 1, 2025, the reporting person was granted nonstatutory stock options under the Company's 2025 Equity Incentive Plan.
• The options allow for the purchase of shares of the Company's Common Stock at an exercise price equal to the closing sales price on the grant date, as quoted by the Nasdaq Stock Market.
• The options will vest in two equal portions at four months and ten months from the grant date and expire ten years from the grant date.

Industry Context

The granting of stock options to directors is a common practice in the biotechnology and broader corporate sectors. It serves as a key component of executive compensation packages, designed to attract and retain talent while aligning leadership's financial incentives with shareholder value creation. This particular grant is consistent with standard industry practices for equity-based compensation.

Comparison to Industry Standards

• Stock option grants are a standard form of executive and director compensation across various industries, including biotechnology, aiming to align the interests of leadership with long-term shareholder value.
• The vesting schedule of two equal portions over ten months is a common structure, providing a near-term incentive while encouraging continued service.
• An exercise price set at the closing market price on the grant date is typical for nonstatutory stock options, ensuring the options only gain value if the company's stock price appreciates.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for minor future dilution if options are exercised, but also benefits from increased alignment of director's interests with stock performance.
• Employees: No direct impact mentioned, but the existence of an equity incentive plan may signal similar opportunities for other key personnel.

Next Steps

• The first portion of the options will vest on February 1, 2026.
• The second portion of the options will vest on August 1, 2026.

Key Dates

Keywords

XBiotech, XBIT, Stock Options, Director Compensation, Equity Incentive Plan, Insider Transaction, Form 4, Biotech